EUCTR2014-003740-13-FR进行中（未招募）不适用
A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients -OAsIs - OAsIs
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age =18 and =80 for French patients, Age =16 and =80 for English patients
- •Relapse or refractory histologically confirmed (according to the ECOG classification) MCL within 3 months before C1D1. The diagnosis has to be confirmed by phenotypic expression of CD5, CD20 and cyclin D1 or the t(11;14) translocation.
- •Relapsed / refractory disease after at least one line of treatment (an additional cohort of 15 untreated MCL patients will be discussed with DSMC after completion of step 2)
- •Stage II-IV in need of treatment
- •ECOG performance status of 0 – 2.
- •Hematology values must be within the following limits:
- •a.Absolute neutrophil count (ANC) =1000/mm3 independent of growth factor support
- •b.Platelets=100,000/mm3 or = 50,000/mm3 if bone marrow involvement and independent of transfusion support in either situation
- •Biochemical values within the following limits:
- •a.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x upper limit of normal (ULN)
- •b.Total bilirubin = 1.5 x ULN unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin
- •c.Serum creatinine = 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault11) = 50 mL/min/1.73m2
- •HIV, anti-HBc, HbsAg test negative
- •Life expectancy of more than 3 months.
- •Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 18 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug.
- •Women of childbearing potential must have a negative serum or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.
- •Written signed informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.
- •Major surgery within 4 weeks of randomization.
- •Known central nervous system lymphoma.
- •History of stroke or intracranial hemorrhage within 6 months prior to randomization.
- •Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon).
- •Impaired liver, renal (GFR<50ml/min) or other organ function which will interfere with the treatment.
- •Requires treatment with strong CYP3A inhibitors.
- •Vaccinated with live, attenuated vaccines within 4 weeks of randomization.
- •Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics. (patients HbsAg+and/or antiHBc+ and/or HIV+ are excluded)
- •Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
- •Known hypersensitivity to study treatment (GA101, Ibrutinib, GDC-0199) or to any of the excipients.
- •Known allergy to xanthine oxidase inhibitors and rasburicase
- •Severe prior reactions to monoclonal antibodies or with prior significant toxicity (other than thrombocytopenia) from Bcl-2 inhibitor
- •History of prior other malignancy with the exception of: Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study
- •Other cancers not specified above which have been curatively treated by surgery alone and from which subject is disease-free for =5 years without further treatment.
- •Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study.
- •Pregnancy/lactation
- •Men or women of reproductive potential not agreeing to use acceptable method of birth control during treatment and for six months after completion of treatment.
- •Use of any standard or experimental anti-cancer drug therapy within 28 days prior to the first dose of study drug.
研究者
相似试验
进行中（未招募）
1 期
A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in RElasped/Refractory Mantle Cell Lymphoma patients - OasIsMedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Mantle Cell LymphomaEUCTR2014-003740-13-GBCentre Hospitalier Universiaire de Nantes33
已完成
1 期
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsMantle Cell LymphomaNCT02558816Nantes University Hospital48
进行中（未招募）
1 期
A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphomarituximab refractory follicular lymphomaMedDRA version: 16.1 Level: LLT Classification code 10016896 Term: Follicle centre lymphoma diffuse small cell lymphoma NOS System Organ Class: 100000004864EUCTR2013-004635-69-NLVU University Medical Center25
已完成
不适用
Therapy with obinutuzumab for patients with lymphomarituximab-refractory follicular lymphomain Dutch: rituximab-refractair folliculair lymfoomNL-OMON26469VU University Medical Center25
招募中
不适用
Therapy with obinutuzumab for patients with lymphomarituximab-refractory follicular lymphomain Dutch: rituximab-refractair folliculair lymfoomNL-OMON24035VU University Medical Center25